WPD Pharmaceuticals WKN: A2PX9R ISIN: CA92941F1053 Kürzel: 8SV1 Forum: Aktien Thema: Hauptdiskussion

https://www.boersennews.de/nachrichten/artikel/irw-news---wpd-pharmaceuticals-inc---wpd-pharmaceuticals-beauftragt-worldwide-clinical-trials-als-cro-mit-weiterer-unterstuetzung-von-studien-ueber-berubicin/2817027/ Viele gute Nachrichten im Moment. 😊

Seit einem 3/4 Jahr nur abwärts... hatte schon 80% minus, habe nachgekauft und rechne damit alles zu verlieren, dachte das wird eine Depotleiche. 🤣🕯

Mit 15% noch im minus aber immerhin wieder etwas Hoffnung...

Bei Mountain Valley MD hats auch gedauert bis der Ausbruch gekommen ist.....wird schon werden.....Seitwärtstrend ist nichts schlechtes....und die News werden schon noch vom Markt aufgenommen werden.

Schlicht für mich aktuell DAS Schnäppchen am Bio-Technologie Markt! Wer WPD und Entwicklungspartner Moleculin nicht auf dem Schirm oder bereits im Depot hat ... 🥁💤😁

Hier tut sich richtig was, wenn Anwendbare Medikamente zur Verfügung stehen

Kann mir das einer erklären, gute News und die Aktie geht in den Keller 🤷🏻‍♀️😳

Aber die Biotechs unter 100mio MK sind derzeit immer für einen Sprung nach oben bereit. Und der Chart sieht hier stabil und erwartungsfroh aus ...

Hätte können mehr zünden die News.

Da haben wir doch die Neuigkeiten die wir hier brauchen...💪💪💪

interessante Chartposition ...

https://m.onvista.de/news/irw-news-wpd-pharmaceuticals-inc-lizenzgeber-von-wpd-pharmaceuticals-erzielt-im-tiermodell-zur-behandlung-von-lungenmetastasen-des-osteosarkoms-mit-annamycin-eine-ueberlebensrate-von-100-432342105

hier auch auf deutsch, siehe Link. Vor 30min veröffentlicht von WPD.

WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug Potentially significant therapeutic benefit against metastatic, Annamycin shown to reach "sanctuary sites" of cancer   Vancouver, British Columbia – Feb 5, 2021 – WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that that Moleculin Biotech Inc. (NASDAQ:MBRX) (“Moleculin”), the company that sublicenses the compound Annamycin to WPD for 29 countries mainly in Europe, announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. The Moleculin press release of February 2, 2020 states, “This appears to be the result of the high cytotoxic potential of Annamycin previously demonstrated in vitro against sarcoma cells in combination with its high uptake by the lungs where the tumors in this study are localized.  Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals. Osteosarcoma is among a class of tumors that initiate in the bone of patients, with bone-related sarcomas representing the second most common form of sarcoma after soft tissue sarcoma.  While many bone sarcomas can be addressed through surgical removal, it is estimated that as many as 40% of bone sarcomas will eventually metastasize to the lungs, where treatment can become more problematic.  Researchers have more recently referred to the lungs and certain other vital organs as "sanctuary sites" for cancer where tumors can develop out of reach from conventional chemotherapies. Once metastasized to the lungs, if tumors cannot be surgically removed, the primary chemotherapy regimen is the anthracycline doxorubicin (also known as Adriamycin).  While 10% to 30% of patients with sarcoma lung metastases may initially respond to doxorubicin, most will relapse leaving the majority of these patients without an alternative chemotherapy.  Moleculin recently announced findings from its sponsored research showing that doxorubicin has a limited ability to accumulate in the lungs of animals, which may help explain its limited efficacy in this sanctuary site.  Treatment options are further limited because of the inherent cardiotoxicity of currently approved anthracyclines, including doxorubicin, which limits the amount of anthracycline that can be given to patients. Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 34 times the level of doxorubicin, which may account for the 100% survival rate attained in this most recent osteosarcoma lung metastases study.  Importantly, Annamycin has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials of Annamycin for the treatment of acute myeloid leukemia, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin. Moleculin recently announced that the FDA has allowed the Company's request for investigational new drug (IND) status in order to study Annamycin for the treatment of soft tissue sarcoma metastasized to the lungs.  In addition, the FDA granted Orphan Drug Designation for Annamycin for the treatment of soft tissue sarcomas.” Moleculin also stated that it expects that one, and potentially two, clinical trials in sarcoma lung metastases should commence in 2021. WPD has not conducted its own independent confirmation testing of Annamycin and is relying solely on the information contained in Moleculin’s news releases dated February 2, 2021 in providing this information to WPD’s shareholders. About WPD Pharmaceuticals WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules.  WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland. WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia. On Behalf of the Board ‘Mariusz Olejniczak’ Mariusz Olejniczak CEO, WDP Pharmaceuticals

https://www.wpdpharmaceuticals.com/

Das ist für mich kein Argument hier einzusteigen. Ich bräuchte schon ein paar Infos